GenScript ProBio / Genscript
GenScript Life Science Group is a part of GenScript Biotech Corporation. Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop ground breaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a …
Profile
GenScript Biotech Corporation is a global biotechnology company founded in 2002 in New Jersey, USA, that provides life science research services, biologics development, and industrial synthetic biology tools. It operates through three primary platforms: GenScript Life Science Group (research services and products), ProBio (an end-to-end CRDMO for biologics and cell and gene therapy), and Bestzyme (industrial enzymes).
The company is publicly listed on the Hong Kong Stock Exchange (HKEX: 1548). As of December 31, 2025, it employed 6,165 people and served over 265,000 customers across more than 100 countries. In 2025, the group reported US$959.5 million in revenue. The company maintains a significant 47.18% equity interest in Legend Biotech, which focuses on cell therapies.
GenScript remains highly active in 2026. Recent developments include the implementation of the GenScript Business System to drive operational excellence, the expansion of AI-driven automated manufacturing, and a planned spin-off and separate listing of its ProBio subsidiary on the HKEX Main Board, which received approval from the Listing Committee in August 2026.
Sources#
- Industry
- Cosmetics, Diagnostics, Energy, Feed, Industrial chemistry, Seeds & genetics, Textiles & leather
- Topics
- Gene synthesis, sequencing & bio-tools, Synthetic biology platforms & biomanufacturing
- Role
- Research / RTO — “…**R&D** - State-of-the-art research center in Philadelphia ( ) **Leadership (website)** - Shiniu Wei — Chief F…”
Bio-solutions it supplies 0
Not yet cited as a supplier in a graded solution.
What they offer
Products: Catalog Peptide; Diabetes & Obesity Peptides; Neuroscience Peptides; Cosmetic Peptide; Cell Penetrating Peptides; AccuPep + QC; Custom Peptide; TurboTIDE; Neoantigen Peptide; Cyclic Peptide
Certifications: EcoVadis Bronze rating
- Applications
- life science research · gene synthesis · protein expression · antibody development · Diabetes Research · Neuroscience · Cosmetics · Drug Development · Fundamental Research · Biotechnology advancements · Cell and gene therapy · Gene synthesis
- Certifications (website)
- EcoVadis Bronze rating
- Customers & partners
- 20% non-profit organizations · 80% industrial customers · Over 39,000 active customers in 1H
- Production sites
- New Jersey — Improving site utilization rate with 30% YoY growth.; Gene synthesis and protein services · Singapore — 8BD gene to protein services.; Automated gene service · Seattle — Revenue growth over 100%.; mRNA and Gene Fragment services · Piscataway, NJ, USA
- Products (website)
- Catalog Peptide — Extensive range of off-the-shelf peptides for diverse research applications. · Diabetes & Obesity Peptides · Neuroscience Peptides · Cosmetic Peptide · Cell Penetrating Peptides · AccuPep + QC — Reduces experimental troubleshooting, increases data reliability & ensures reproducible results. · Custom Peptide — Tailored peptide synthesis with various modifications. · TurboTIDE — 5-Day Guarantee for custom peptides. · Neoantigen Peptide — Peptides designed for targeted immuno-oncology applications. · Cyclic Peptide — Synthesis of cyclic peptides with optimal stability and function. · GLP-1 Receptor Agonist — Peptide designed for metabolic diseases. · Cosmetic Peptide — Custom peptides for cosmetic applications.
- R&D facilities
- State-of-the-art research center in Philadelphia
Read from the company's own website: about · products · production · quality · rnd · leadership · sustainability · topic
Subsidiaries: Probio Technology Limited (ProBio) · Bestzyme Biotech Corporation (Bestzyme) · Legend Biotech Corporation (Significant investment)
News & status 6
- 2026-08 Latest status: The company is pursuing a spin-off and separate listing of its subsidiary ProBio on the Main Board of the Stock Exchange, which was confirmed by the Listing Committee on 14 August 2026. ↗ ↗ ↗
- 2026-09-16 金斯瑞与礼来TuneLab达成重要合作 紧抓AI赋能战略机遇GenScript (Genscript ProBio) is expanding its AI-driven drug discovery capabilities by partnering with Eli Lilly’s Lilly TuneLab platform to provide wet-lab validation services, bridging AI predictions with experimental data and accelerating candidate …
- 2026-09-23 GenScript's Bestzyme Completes 100-Ton Sweet Protein Line in China - vegconomist - the vegan business magazineGenScript ProBio/GenScript is expanding into high-capacity, automated sweet-protein production through its Bestzyme subsidiary, demonstrating aggressive bioprocess scale-up (100+ tons/year) and venture into integrated fermentation-to-drying operations to …
- 2026-09-04 Genscript shares slump 12pc on proposed spinoff of Probio Technology – Hong Kong United Times丨Dialogue with the WorldGenScript Biotech’s shares fell about 12% after announcing a proposed spin-off and separate listing of its subsidiary ProBio Technology (Probio Technology). ProBio would remain a subsidiary with GenScript holding a controlling stake, and its financials would …
- 2026-09-16 GENSCRIPT BIOTECH | Brief: ProBio & Kun Tuo Announce Strategic Collaboration To Deliver Integrated CDMO-CRO SolutionsGenscript ProBio (GenScript Biotech unit) and KunTuo announce a strategic collaboration to deliver integrated CDMO-CRO solutions for advanced therapies in China, aiming to accelerate investigator-initiated trials and streamline clinical operations.
- 2026-09-18 Genscript Biotech Corporation Enters Agreement with Eli Lilly and Company to Join Lilly TuneLab Collaborative AI-Enabled Drug Discovery Platform | MarketScreener Hong KongGenScript Biotech Corporation (Genscript) has entered an agreement to join Eli Lilly’s TuneLab AI-enabled drug discovery platform, offering preferred-rate wet-lab services to TuneLab members to convert AI predictions into biological data, signaling expanded …
- 2026-09-17 GENSCRIPT BIOTECH | GenScript Biotech hits near 5-year high on Eli Lilly collaborationGenScript Biotech is rallying after announcing a collaboration with Lilly TuneLab (Eli Lilly’s AI-driven drug discovery platform), with GenScript providing wet-lab services to translate AI predictions into validated data, helping accelerate drug candidate …
Network: owners, partners, peers
Ownership & investors 4
| parent | Genscript Biotech Corporation |
| subsidiary | Pherobio Technology Co., Ltd |
| subsidiary | Bestzyme Biotech Corporation |
| subsidiary | Legend Biotech Corporation |
Similar companies
Tsingke Biotech · Aurisco Pharmaceutical Co.,Ltd · Takara Bio Inc. · ST PHARM · Pepmic Co., Ltd · Bioplus Life Sciences · OBiO Tech · WuXi Biologics
Identity & contacts
Contacts, people and legal identity are available to members.
Sign in as a member